SEC Filing | PDL BioPharma, Inc.

View:

Download DOC

Download PDF

Download XLS

pdl_8k-050913.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 9, 2013

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756

(Commission File Number)

Delaware	94-3023969
(State or Other Jurisdiction of	(I.R.S. Employer Identification No.)
Incorporation)

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company’s telephone number, including area code)

________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2013, PDL BioPharma, Inc. (the Company) issued a press release announcing the financial results for the first quarter ended March 31, 2013. A copy of this earnings release is attached hereto as Exhibit 99.1. The Company will host an earnings call and webcast on May 9, 2013, during which the Company will discuss its financial results for the first quarter ended March 31, 2013.

Item 7.01 Regulation FD Disclosure.

Presentation Materials

On May 9, 2013, the Company posted to its website a set of presentation materials that it will use during its earnings call and webcast to assist participants with understanding the Company’s financial results. A copy of this presentation is attached hereto at Exhibit 99.2

Information Sheet

On May 9, 2013, the Company distributed to analysts covering the Company’s securities a summary of certain information regarding the Company’s net income, dividends, acquisitions and licensed product development and sales (the Information Sheet) to assist those analysts in valuing the Company’s securities. The Information Sheet and its associated tables are attached hereto as Exhibit 99.3.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibits, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Cautionary Statements

This filing and its exhibits include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s Annual Report on Form 10-K, as updated by subsequent quarterly reports, filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1 99.2 99.3		Press Release Presentation Information Sheet

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PDL BIOPHARMA, INC. (Company)

	By:	/s/ John P. McLaughlin
		John P. McLaughlin President, Chief Executive Officer and Acting Chief Financial Officer

Dated: May 9, 2013

EXHIBIT INDEX

Exhibit No.		Description
99.1 99.2 99.3		Press Release Presentation Information Sheet

ex99-1.htm

Exhibit 99.1

Contacts:
John McLaughlin	Jennifer Williams
PDL BioPharma, Inc.	Cook Williams Communications
775-832-8500	360-668-3701
john.mclaughlin@pdl.com	jennifer@cwcomm.org

PDL BioPharma Announces First Quarter 2013 Financial Results

INCLINE VILLAGE, NV, May 9, 2013 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2013.

Royalty revenues for the first quarter of 2013 increased 19 percent over the same period of 2012. Total revenues for the first quarter of 2013 were $91.8 million compared to $77.3 million for the same period in 2012.

Royalty revenues for the first quarter of 2013 are based on fourth quarter 2012 product sales by PDL’s licensees. The growth in royalty revenues was driven primarily by increased royalties from fourth quarter 2012 sales of Avastin®, Herceptin®, Lucentis®, Tysabri®, and Actemra®.

General and administrative expenses for the first quarter of 2013 were $7.2 million compared with $6.9 million in the same period of 2012.

Net income for the first quarter of 2013 was $53.5 million or $0.36 per diluted share as compared with $40.2 million, or $0.29 per diluted share in the comparable quarter of 2012. The increase in net income is due to the 19 percent increase in royalty revenues and the resulting 33 percent increase in net income.

Net cash provided by operating activities in the first quarter of 2013 was $54.0 million compared with net cash provided by operating activities of $17.9 million for the first quarter of 2012. At March 31, 2013, PDL had cash, cash equivalents and investments of $187.2 million, compared with $148.7 million at December 31, 2012.

Recent Developments

Structured Financing and Royalty Transaction with Avinger

On April 18, 2013, PDL entered into a Credit Agreement with Avinger, Inc. The total financing of up to $40 million was provided pursuant to a Credit Agreement that included $20 million in cash funded to Avinger on April 18, 2013, and up to $20 million in additional funds to Avinger upon the accomplishment of certain specified revenue milestones. In exchange, PDL will receive interest on the principal amount outstanding and a low, single-digit royalty on Avinger’s revenues from the sale of Avinger’s suite of products through April 2018. Avinger is a designer of therapeutic devices incorporating intravascular imaging, and is a pioneer of the lumivascular approach to treating vascular disease. This financing assists Avinger in the commercialization of its currently marketed OcelotTM and LightboxTM next-generation lumivascular catheter devices used to open totally occluded arteries in the legs, and in the development of PantherisTM, Avinger's next-generation lumivascular atherectomy device.

Peter Garcia Appointed Vice President and Chief Financial Officer

On May 13, 2013, Peter S. Garcia will join PDL as vice president, chief financial officer (CFO) and chief accounting officer. Mr. Garcia has spent the last 16 years in various CFO positions for biotechnology companies. He joins PDL from BioTime, Inc. (NYSE MKT: BTX) where he served as CFO since 2011.

2013 Dividends

On January 30, 2013, PDL’s Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 12, June 12, September 12 and December 12 of 2013 to all stockholders who own shares of PDL on March 5, June 5, September 5 and December 5 of 2013, the record dates for each of the dividend payments, respectively. On March 12, 2013, PDL paid the first quarterly dividend to stockholders of record totaling $21 million using earnings generated in the first quarter of 2013.

Revenue Guidance for 2013

As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. Second quarter 2013 revenue guidance will be provided in early June.

Conference Call Details

PDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, May 9, 2013.

To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through May 15, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 59911834.

To access the live and subsequently archived webcast of the conference call, go to the Company’s website at http://www.pdl.com and go to “Events & Presentations.” Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME DATA

(Unaudited)

(In thousands, except per share amounts)

	Three Months Ended
	March 31,
	2013			2012
Revenues
Royalties	$	91,847		$	77,344
License and other		-			-
Total revenues		91,847			77,344
Operating Expenses
General and administrative expenses		7,186			6,945
Operating income		84,661			70,399
Non-operating expense, net
Interest and other income, net		3,838			90
Interest expense		(6,000	)		(8,700	)
Total non-operating expense, net		(2,162	)		(8,610	)
Income before income taxes		82,499			61,789
Income tax expense		29,028			21,605
Net income	$	53,471		$	40,184

Net income per share
Basic	$	0.38		$	0.29
Diluted	$	0.36		$	0.29

Shares used to compute income per basic share		139,816			139,680
Shares used to compute income per diluted share		149,101			140,204

Cash dividends declared per common share	$	0.60		$	0.60

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEET DATA

(Unaudited)

(In thousands)

	March 31,			December 31,
	2013			2012
Cash, cash equivalents and investments	$	187,213		$	148,689
Total notes receivable	$	90,184		$	93,208
Total assets	$	312,810		$	279,966
Convertible notes payable	$	312,613		$	309,952
Total stockholders' deficit	$	(93,671	)	$	(68,122	)

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA

(Unaudited)

(In thousands)

	Three Months Ended
	March 31,
	2013			2012
Net income	$	53,471		$	40,184
Adjustments to reconcile net income to net cash provided by operating activities		3,178			6,215
Changes in assets and liabilities		(2,649	)		(28,503	)
Net cash provided by operating activities	$	54,000		$	17,896

PDL BIOPHARMA, INC.

MIX OF EX-U.S. SALES AND EX-U.S.-BASED MANUFACTURING AND SALES

OF GENENTECH PRODUCTS

(Unaudited)

		Three Months Ended March 31,
		2013		2012
Avastin
	% Ex-U.S. Sold	60	%	57	%
	% Ex-U.S.-based Manufactured and Sold	50	%	27	%
Herceptin
	% Ex-U.S. Sold	69	%	70	%
	% Ex-U.S.-based Manufactured and Sold	41	%	35	%
Lucentis
	% Ex-U.S. Sold	67	%	60	%
	% Ex-U.S.-based Manufactured and Sold	0	%	0	%
Perjeta
	% Ex-U.S. Sold	5	%	0	%
	% Ex-U.S.-based Manufactured and Sold	0	%	0	%
Xolair
	% Ex-U.S. Sold	39	%	40	%
	% Ex-U.S.-based Manufactured and Sold	39	%	40	%

ex99-2.htm

Exhibit 99.2

ex99-3.htm

Exhibit 99.3

PDL BioPharma, Inc.

Q1-2013

May 9, 2013

Following are some of the key points regarding PDL’s first quarter 2013 financial and business results.

Net Income

2013 Dividends

·	On March 12, 2013, PDL paid the first quarterly dividend to stockholders of record totaling $21 million using earnings generated in the first quarter of 2013.

Income Generating Assets

·	Closed three significant transactions in 2012 and one so far in 2013

·	Credit Agreement / Royalty Transaction with Avinger, Inc. on April 18, 2013

PDL financing Avinger for $40 million, including $20 million cash funded on April 18 and up to $20 million more upon completion of certain revenue milestones.

PDL to receive interest on the principal and a low single-digit royalty on Avinger’s revenues from product sales through April 2018.

Avinger has developed a new technology and a new approach to treatment of vascular disease called lumivascular (lumi = light, vascular = artery). Already commercially available is Ocelot, the first line of devices using lumivascular technology, used in procedures to open totally occluded arteries in the legs. The company is also developing a line of lumivascular atherectomy devices, called Pantheris, which will be used to remove plaque from the arteries affected by peripheral artery disease.

Updates on Approved Royalty Bearing Products

Avastin® (bevacizumab):

·	On April 11, 2013, Genentech/Roche reported that 1Q13 worldwide sales increased by 11% on a constant exchange basis.

In EU, higher sales were driven by increased use in ovarian cancer and metastatic colorectal cancer.

In US, increased sales also reflected greater use in the treatment of metastatic colorectal cancer through multiples lines.

In Japan, Avastin experienced steady growth in non-small cell lung cancer.

·	On December 12, 2012, Genentech/Roche announced that EMA approved the use of Avastin in second line metastatic colorectal cancer.

·	On January 24, 2013, FDA granted a similar approval.

At ASCO, Genentech/Roche will present additional data from the previously announced NIH trial in patients with recurrent and metastatic cervical cancer comparing Avastin plus two chemotherapies against two chemotherapies that met its primary endpoint of improving median overall survival by 3.7 months.

Herceptin® (trastuzumab):

·	On April 11, 2013, Genentech/Roche reported that 1Q13 worldwide sales increased by 11% on a constant exchange basis.

Much of the growth was seen in US and emerging markets.

PDL BioPharma, Inc.

Q1-2013

May 9, 2013

Lucentis® (ranibizumab):

·	On April 11, 2013, Genentech/Roche reported that 1Q13 US sales increased by 1% on a constant exchange basis.

In US, Roche said that the competitive environment in age-related macular degeneration remains challenging, that share is stable in retinal vein occlusion and that it is increasing in diabetic macular edema.

·	On April 24, 2013, Novartis reported that 1Q13 ex-US sales increased by 7% on a constant exchange basis.

Ex-US, Lucentis is facing competition in several markets, including Japan, Australia and Germany, from Eylea.

Actemra® (tocilizumab):

·	On April 11, 2013, Genentech/Roche reported that 1Q13 worldwide sales increased by 32% on a constant exchange basis.

Sales growth was driven by monotherapy use with US being the biggest contributor to growth.

·	On April 30, 2013, Genentech/Roche announced that FDA had approved its use for the treatment of a rare, debilitating condition in children known as polyarticular juvenile idiopathic arthritis.

Perjeta™ (pertuzumab):

·	On April 11, 2013 Genentech/Roche reported 1Q13 sales of CHF 50 million.

·	Genentech/Roche announced EMA approval in March 2013.

·	Genentech/Roche expects to file in 2Q13 for approval in US in neo-adjuvant setting for HER2+ breast cancer.

Kadcyla™ (TDM-1 or ado-trastuzumab emtansine):

·	On April 13, 2013, Genentech/Roche reported 1Q13 sales of CHF 18 million.

Already included in National Comprehensive Cancer Network (NCCN) guidelines.

Enrolled first patient in April 2013 in Phase 3 in adjuvant setting under SPA in US

Updates on Select Development Stage Potential Royalty Bearing Products

Obinutuzumab:

At ASCO, Genentech/Roche will present additional data from previously announced Stage 1 of Phase 3 trial in patients with previously untreated chronic lymphocytic leukemia that showed treatment with obinutuzumab plus chemotherapy significantly reduced the risk of disease worsening or death compared to treatment with chemotherapy.

Stage1 also included a pre-planned progression-free-survival (PFS) futility analysis comparing obinutuzumab plus chemotherapy to Rituxan plus chemotherapy. The goal of the futility analysis was to evaluate the likelihood that the study would meet its pre-specified endpoint criteria during Stage 2 analysis - improved efficacy (PFS) in the direct comparison of obinutuzumab plus chemotherapy to Rituxan plus chemotherapy.

The independent Data and Safety Monitoring Board (DSMB) assessment concluded that Stage 2 of the study should continue until its final analysis.

Forward-looking Statements

This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new income generating assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Page 2

PDL BioPharma, Inc.

Q1-2013

May 9, 2013

Royalty Revenue by Product ($ in 000's) *


Avastin	Q1	Q2	Q3	Q4	Total
2013	33,234	-	-	-		33,234
2012	23,215	41,670	25,955	30,041		120,882
2011	22,283	41,967	23,870	22,886		111,006
2010	16,870	44,765	29,989	24,922		116,547
2009	13,605	35,161	21,060	15,141		84,966
2008	9,957	30,480	19,574	12,394		72,405
2007	8,990	21,842	17,478	9,549		57,859
2006	10,438	15,572	15,405	12,536		53,952

Herceptin	Q1	Q2	Q3	Q4	Total
2013	30,287	-	-	-		30,287
2012	25,702	44,628	30,433	28,307		129,070
2011	25,089	42,209	31,933	21,812		121,042
2010	23,402	38,555	27,952	25,441		115,350
2009	16,003	32,331	26,830	18,615		93,779
2008	14,092	34,383	28,122	20,282		96,880
2007	19,035	28,188	22,582	14,802		84,608
2006	15,142	19,716	21,557	20,354		76,769

Lucentis	Q1	Q2	Q3	Q4	Total
2013	12,032	-	-	-		12,032
2012	10,791	27,938	12,552	11,097		62,377
2011	8,878	24,313	12,157	10,750		56,099
2010	7,220	19,091	10,841	8,047		45,198
2009	4,621	12,863	8,123	6,152		31,759
2008	3,636	11,060	7,631	4,549		26,876
2007	2,931	6,543	6,579	3,517		19,570
2006	-	-	289	3,335		3,624

Xolair	Q1	Q2	Q3	Q4	Total
2013	5,930	-	-	-		5,930
2012	5,447	8,609	6,504	6,145		26,705
2011	4,590	7,621	5,916	5,823		23,949
2010	3,723	6,386	4,980	4,652		19,741
2009	2,665	5,082	4,085	3,722		15,553
2008	1,488	4,866	3,569	2,927		12,850
2007	1,684	3,942	3,332	2,184		11,142
2006	2,263	2,969	3,041	2,495		10,768

Perjeta	Q1	Q2	Q3	Q4	Total
2013	340	-	-	-		340
2012	-	-	58	250		308
2011	-	-	-	-		-
2010	-	-	-	-		-
2009	-	-	-	-		-
2008	-	-	-	-		-
2007	-	-	-	-		-
2006	-	-	-	-		-

Tysabri	Q1	Q2	Q3	Q4	Total
2013	12,965	-	-	-		12,965
2012	11,233	12,202	11,749	12,255		47,439
2011	9,891	10,796	11,588	11,450		43,725
2010	8,791	8,788	8,735	9,440		35,754
2009	6,656	7,050	7,642	8,564		29,912
2008	3,883	5,042	5,949	6,992		21,866
2007	839	1,611	2,084	2,836		7,370
2006	-	-	-	237		237

Actemra	Q1	Q2	Q3	Q4	Total
2013	2,631	-	-	-		2,631
2012	1,705	2,074	2,145	2,462		8,385
2011	913	1,136	1,401	1,460		4,910
2010	1,587	237	315	688		2,827
2009	585	537	909	1,197		3,228
2008	44	-	146	369		559
2007	32	-	-	17		49
2006	-	-	-	-		-

* As reported to PDL by its licensees
Totals may not sum due to rounding

Page 3

PDL BioPharma, Inc.

Q1-2013

May 9, 2013

Reported Net Sales Revenue by Product ($ in 000's) *


Avastin	Q1	Q2	Q3	Q4	Total
2013	1,653,108	-	-	-		1,653,108
2012	1,502,757	1,573,727	1,551,327	1,662,977		6,290,788
2011	1,597,461	1,582,705	1,581,095	1,469,994		6,231,255
2010	1,506,788	1,596,892	1,594,707	1,646,218		6,344,605
2009	1,345,487	1,295,536	1,439,730	1,514,053		5,594,806
2008	980,715	1,084,930	1,180,427	1,239,382		4,485,454
2007	678,068	746,587	797,013	875,084		3,096,752
2006	439,318	516,052	570,551	592,897		2,118,817

Herceptin	Q1	Q2	Q3	Q4	Total
2013	1,681,574	-	-	-		1,681,574
2012	1,515,255	1,625,313	1,663,695	1,650,495		6,454,759
2011	1,391,568	1,559,975	1,642,898	1,432,771		6,027,211
2010	1,270,846	1,349,512	1,300,934	1,409,310		5,330,602
2009	1,210,268	1,133,993	1,226,435	1,278,626		4,849,323
2008	1,105,426	1,195,215	1,211,982	1,186,806		4,699,428
2007	891,761	949,556	979,602	1,015,033		3,835,952
2006	529,585	659,719	761,099	803,576		2,753,979

Lucentis	Q1	Q2	Q3	Q4	Total
2013	1,203,179	-	-	-		1,203,179
2012	1,079,092	1,086,543	1,097,541	1,109,695		4,372,871
2011	887,757	943,418	1,052,809	1,075,015		3,958,999
2010	721,967	698,890	745,376	804,684		2,970,917
2009	462,103	469,736	555,296	615,212		2,102,347
2008	363,615	393,682	460,167	454,922		1,672,386
2007	224,820	219,579	299,995	322,300		1,066,695
2006	-	-	10,689	157,742		168,431

Xolair	Q1	Q2	Q3	Q4	Total
2013	341,309	-	-	-		341,309
2012	310,234	314,638	347,796	340,431		1,313,100
2011	267,754	277,642	310,874	314,911		1,171,182
2010	228,859	225,878	251,055	263,389		969,179
2009	184,669	181,086	211,006	219,693		796,454
2008	137,875	169,521	177,179	183,753		668,329
2007	129,172	130,700	144,250	147,754		551,876
2006	95,241	99,354	112,608	118,002		425,204

Perjeta	Q1	Q2	Q3	Q4	Total
2013	34,008	-	-	-		34,008
2012	-	-	5,080	25,000		30,079
2011	-	-	-	-		-
2010	-	-	-	-		-
2009	-	-	-	-		-
2008	-	-	-	-		-
2007	-	-	-	-		-
2006	-	-	-	-		-

Tysabri	Q1	Q2	Q3	Q4	Total
2013	434,677	-	-	-		434,677
2012	374,430	401,743	391,623	408,711		1,576,508
2011	329,696	356,876	388,758	381,618		1,456,948
2010	293,047	287,925	293,664	316,657		1,191,292
2009	221,854	229,993	257,240	285,481		994,569
2008	129,430	163,076	200,783	233,070		726,359
2007	30,468	48,715	71,972	94,521		245,675
2006	-	-	-	7,890		7,890

Actemra	Q1	Q2	Q3	Q4	Total
2013	87,703	-	-	-		87,703
2012	56,662	66,624	71,505	82,053		276,843
2011	30,433	35,370	46,709	48,671		161,183
2010	52,908	5,405	10,493	22,919		91,725
2009	19,504	17,920	30,313	39,888		107,625
2008	1,452	1,377	5,981	12,305		21,115
2007	-	-	-	1,137		1,137
2006	-	-	-	-		-

* As reported to PDL by its licensees
Totals may not sum due to rounding

Page 4

PDL BioPharma, Inc.

Q1-2013

May 9, 2013

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4		2013 - Q1
US Made & Sold	684,878		652,824		724,483		679,914		710,501		664,109
US Made & ex-US Sold	375,830		448,037		532,979		428,976		281,905		161,369
ex-US Made & Sold	409,286		401,896		316,265		442,437		670,572		827,629
Total	1,469,994		1,502,757		1,573,727		1,551,327		1,662,977		1,653,108
US Made & Sold	47	%	43	%	46	%	44	%	43	%	40	%
US Made & ex-US Sold	26	%	30	%	34	%	28	%	17	%	10	%
ex-US Made & Sold	28	%	27	%	20	%	29	%	40	%	50	%

Herceptin Sales	2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4		2013 - Q1
US Made & Sold	453,168		456,920		497,109		503,612		515,790		514,113
US Made & ex-US Sold	612,908		523,353		466,477		545,625		552,127		486,400
ex-US Made & Sold	366,695		534,982		661,727		614,459		582,578		681,060
Total	1,432,771		1,515,255		1,625,313		1,663,695		1,650,495		1,681,574
US Made & Sold	32	%	30	%	31	%	30	%	31	%	31	%
US Made & ex-US Sold	43	%	35	%	29	%	33	%	33	%	29	%
ex-US Made & Sold	26	%	35	%	41	%	37	%	35	%	41	%

Lucentis Sales	2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4		2013 - Q1
US Made & Sold	428,884		433,428		412,131		385,746		381,592		392,207
US Made & ex-US Sold	646,131		645,665		674,411		711,795		728,103		810,972
ex-US Made & Sold	-		-		-		-		-		-
Total	1,075,015		1,079,092		1,086,543		1,097,541		1,109,695		1,203,179
US Made & Sold	40	%	40	%	38	%	35	%	34	%	33	%
US Made & ex-US Sold	60	%	60	%	62	%	65	%	66	%	67	%
ex-US Made & Sold	0	%	0	%	0	%	0	%	0	%	0	%

Xolair Sales	2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4		2013 - Q1
US Made & Sold	188,728		185,505		193,600		211,702		210,892		207,976
US Made & ex-US Sold	-		-		-		-		-		-
ex-US Made & Sold	126,184		124,729		121,039		136,094		129,540		133,333
Total	314,911		310,234		314,638		347,796		340,431		341,309
US Made & Sold	60	%	60	%	62	%	61	%	62	%	61	%
US Made & ex-US Sold	0	%	0	%	0	%	0	%	0	%	0	%
ex-US Made & Sold	40	%	40	%	38	%	39	%	38	%	39	%

Perjeta Sales	2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4		2013 - Q1
US Made & Sold	-		-		-		5,080		24,571		32,377
US Made & ex-US Sold	-		-		-		-		428		1,632
ex-US Made & Sold	-		-		-		-		-		-
Total	-		-		-		5,080		25,000		34,008
US Made & Sold	0	%	0	%	0	%	100	%	98	%	95	%
US Made & ex-US Sold	0	%	0	%	0	%	0	%	2	%	5	%
ex-US Made & Sold	0	%	0	%	0	%	0	%	0	%	0	%

Total Sales	2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4		2013 - Q1
US Made & Sold	1,755,657		1,728,678		1,827,323		1,786,053		1,843,345		1,810,783
US Made & ex-US Sold	1,634,869		1,617,054		1,673,867		1,686,395		1,562,564		1,460,373
ex-US Made & Sold	902,165		1,061,607		1,099,031		1,192,990		1,382,690		1,642,023
Total	4,292,691		4,407,339		4,600,221		4,665,438		4,788,598		4,913,178
US Made & Sold	41	%	39	%	40	%	38	%	38	%	37	%
US Made & ex-US Sold	38	%	37	%	36	%	36	%	33	%	30	%
ex-US Made & Sold	21	%	24	%	24	%	26	%	29	%	33	%

* As reported to PDL by its licensees
Totals may not sum due to rounding

Page 5